Skip to main content
Bioversys N logo

Bioversys N — Investor Relations & Filings

Ticker · BIOV ISIN · CH0210362643 LEI · 894500UFIGC75NPZEZ68 SW Manufacturing
Open in API
Filings indexed 78 across all filing types
Latest filing 2025-12-11 Regulatory Filings
Country CH Switzerland
Listing SW BIOV

About Bioversys N

https://www.bioversys.com/

Bioversys is a clinical-stage biopharmaceutical company focused on the research and development of novel antibacterial therapies to combat the global threat of antimicrobial resistance (AMR). The company develops small molecule drugs that act on novel bacterial targets through innovative modes of action. Its clinical pipeline includes BV100, a treatment for serious hospital infections caused by Acinetobacter baumannii, and Alpibectir, a novel potentiator for multidrug-resistant tuberculosis (MDR-TB). Both candidates are in Phase 2 clinical development. The company's earlier-stage portfolio includes BV200, an anti-virulence compound for Staphylococcus aureus infections, and BV500 for Nontuberculous mycobacteria (NTM) infections, addressing critical unmet medical needs.

Recent filings

Filing Released Lang Actions
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
Regulatory Filings Classification · 1% confidence The document is an 'ad hoc' announcement from BioVersys AG regarding the initiation of a Phase 3 clinical trial for its lead asset, BV100, and a general business update. It follows the standard format of a corporate press release or regulatory announcement (RNS) rather than a full financial report, proxy statement, or transcript. It provides key highlights of company progress, clinical milestones, and financial outlook, fitting the definition of a general regulatory announcement.
2025-12-11 English
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
Regulatory Filings Classification · 1% confidence The document is an 'ad hoc announcement' issued by BioVersys AG regarding the initiation of a Phase 3 clinical trial for its lead asset, BV100, and a general business update. It provides details on clinical progress, partnerships (Shionogi, GSK), and future milestones. It is not a full financial report (10-K/IR), nor is it a transcript or a simple report publication notice. It functions as a corporate update on business and clinical operations, which falls under the 'Regulatory Filings' (RNS) category as it is an official ad hoc announcement pursuant to Art. 53 LR.
2025-12-11 English
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network
Regulatory Filings Classification · 1% confidence The document is an 'Ad-hoc announcement' issued by BioVersys AG regarding the selection of its lead asset, BV100, for a Phase 2b clinical trial conducted by the ADVANCE-ID network. It contains specific details about clinical trial funding, partnership structure, and expected timelines. This type of regulatory disclosure, which provides material information to the market, is classified as a Regulatory Filing (RNS) as it does not fit into specific categories like Earnings Release (no quarterly financial results) or M&A Activity.
2025-11-10 English
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network
Regulatory Filings Classification · 1% confidence The document is an 'ad hoc announcement' issued by BioVersys AG regarding the selection of its lead asset, BV100, for a Phase 2b clinical trial conducted by the ADVANCE-ID network. It details the partnership, funding, and clinical trial scope. As it is a specific regulatory announcement of material corporate news (inside information) that does not fit into categories like earnings releases, annual reports, or shareholder voting, it falls under the 'Regulatory Filings' (RNS) category.
2025-11-10 English
Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA
Regulatory Filings Classification · 1% confidence The document is an 'ad hoc' announcement issued by BioVersys AG regarding the dosing of the first subject in a Phase 1 clinical trial in China. It follows the standard format of a regulatory news release (RNS) for a biopharmaceutical company, providing updates on clinical trial progress and regulatory milestones. It does not fit into specific categories like financial reports, shareholder meetings, or director dealings, making 'RNS' the appropriate classification for this type of corporate regulatory disclosure.
2025-11-06 English
Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA
Regulatory Filings Classification · 1% confidence The document is an 'ad hoc announcement' regarding the dosing of the first subject in a Phase 1 clinical trial for the company's drug candidate, BV100. It provides updates on clinical development progress and regulatory milestones. Since it does not fit into specific categories like financial reports, board changes, or dividend announcements, and is a standard regulatory disclosure of material information, it is classified as a Regulatory Filing (RNS).
2025-11-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.